Caplin Point Laboratories share news, announcements and annual reports
NSE: CAPLIPOINTBSE: 524742Pharmaceuticals & BiotechnologySmall Cap
Caplin Point Laboratories Limited · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Feb 1995 on BSE, Jun 2014 on NSE
Last close ₹2,325.60down ₹50.50 (2.13%)BSE ₹2,324.85
Share price at the NSE close on 30 Oct 2026. Previous close ₹2,376.10.
30 Oct: open ₹2,377.40, high ₹2,422.40, low ₹2,310.00
52-week range of traded prices to 30 Oct 2026
₹1,500.30Low, 30 Mar 2026₹2,990.00High, 24 Sep 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹17,677 Cr453rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 26.57
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 4.93
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.34%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 20.7%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 19.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 1,28,33948.3% delivered
Caplin Point Laboratories share news and announcements
492 announcements, routine notices left out, newest first. Page 9 of 10.
Apr 2017
Feb 2017
10 Feb · Disclosure
6 Feb · Results
Jan 2017
Nov 2016
11 Nov · Analysts
9 Nov · Legal
Exchange has sought clarification from Caplin Point Laboratories Limited with respect to announcement dated 09-Nov-2016, regarding "Caplin Point Laboratories Limited has informed the Exchange that The Board of Directors of the Company at their meeting held November 09, 2016, appointed Mr D Sathyanarayanan as an Additional Director (Non-Executive-Independent) with effect from November 09,2016".On basis of above the Company is required to clarify following:1. Brief profile (in case of appointment);2. Disclosure of relationships between directors (in case of appointment of a director).The response of the Company is awaited.9 Nov · Results
Oct 2016
Sep 2016
Aug 2016
5 Aug · Corporate action
Board of Directors of the Company at their Meeting held on August 05, 2016, have approved the Sub-division of existing Equity Shares of Face Value of Rs.10/- each into(5) Five Equity Shares of face value of Rs.2/- each, subject to the approval of Members of the Company at the ensuing Annual General Meeting and Regulatory/ Statutory Approvals
Jul 2016
May 2016
27 May · Dividend
Board of Directors of the Company at its meeting held on May 27, 2016, have recommended a Final Dividend of Rs.3.50 (35%) on face value of Rs.10 each for nine months /Financial year ended March 31,2016.
Apr 2016
Mar 2016
Feb 2016
Jan 2016
Nov 2015
Oct 2015
Sep 2015
Aug 2015